2017 As a part of the process to bring Boule to the next level, the company reformulates its mission, vision and business concept, and new strategies, targets and core values are implemented.
2015 A new instrument generation is introduced.
2014 A new product generation is introduced. Boule relocates the Swedish operations to Spånga in north Stockholm.
2013 A subsidiary in Mexico and sales office in India are established.
2011 Boule is listed on Nasdaq Stockholm.
2010 The Quintus 5-part system is launched.
2009 The Medonic M-series systems receive 510(k) clearance in the US.
2007 CDS obtains ISO certification, entailing that all companies in the Group now hold ISO 13485 certification.
2006 The company launches a new instrument generation based on ashared platform for Medonic and Swelab instruments.
2004 Boule’s hematology system, Medonic CA 620, receives 510(k) clearance in the US. Boule acquires its partner CDS.
2003 Boule establishes reagent manufacturing for blood cell counting in Sweden.
2002 Cooperation with the American company Clinical Diagnostic Solutions Inc. (’CDS’) begins. CDS develops, produces and markets reagents and blood controls for clinical diagnostics in hematology.
2001 Boule conducts a private placement to fund the development of the new core business, hematology systems for human and veterinary markets.
1998 Boule acquires the instrument manufacturer Medonic AB, founded in the 1980s. Boule becomes ISO certified.
1997 Boule acquires the instrument manufacturer Swelab Instrument AB. Swelab was formed as early as the 1950s.
1996 Boule Diagnostics AB (’Boule’) is formed as parent company for the Group.
1992 Karo Bio Diagnostics AB is acquired by the present principal owner of Boule Diagnostics AB.
1990 The company Karo Bio Diagnostics AB is founded.
1982 Medonic AB founded by Ingemar Berndtsson and Bram Bottema.
1969 Swelab Instrument AB founded by Erik Öhlin.
1956 The first European cell counter developed by Erik Öhlin.